Loading...
Market
Number of Chinese cities where Leqembi is available by December 31, 2024
3
Resolution / Starting Odds
1-10 cities • 25%
11-20 cities • 25%
21-30 cities • 25%
More than 30 cities • 25%
Public announcements or official reports from Eisai/Biogen or Chinese regulatory authorities
Story
Eisai and Biogen Launch Alzheimer's Drug Leqembi in China at USD24,800 per Year
Jun 27, 2024, 11:37 PM
Eisai and Biogen have launched their Alzheimer's treatment Leqembi in China, marking the third country after the United States and Japan to approve the drug. The treatment, which was approved by the Chinese regulator in January, is expected to be put into clinical use in Chinese hospitals, according to a hospital staffer in Shanghai. Leqembi, also known as Lecanemab, will cost CNY180,000 (USD24,800) per one-year cycle. This development signifies a significant step in the availability of advanced Alzheimer's treatments in China.
View original story
Similar markets
Less than 20 cities • 25%
20-40 cities • 25%
41-60 cities • 25%
More than 60 cities • 25%
Fewer than 10 cities • 25%
10 to 20 cities • 25%
20 to 30 cities • 25%
More than 30 cities • 25%
11 or fewer • 25%
12-14 • 25%
15-17 • 25%
18 or more • 25%
Beijing • 25%
Shanghai • 25%
Shenzhen • 25%
Other • 25%
Less than 10 cities • 25%
10 to 20 cities • 25%
20 to 30 cities • 25%
More than 30 cities • 25%
Shanghai • 25%
Beijing • 25%
Guangzhou • 25%
Other • 25%
More than $500 million • 25%
$300 million to $500 million • 25%
$100 million to $300 million • 25%
Less than $100 million • 25%
None • 25%
1-2 cities • 25%
3-4 cities • 25%
5 or more cities • 25%
Yes • 50%
No • 50%
High uptake (over 10,000 patients) • 25%
Moderate uptake (5,000-10,000 patients) • 25%
Low uptake (1,000-5,000 patients) • 25%
Very low uptake (under 1,000 patients) • 25%
0-5 cities • 25%
6-10 cities • 25%
11-15 cities • 25%
16 or more cities • 25%
Beijing • 25%
Shanghai • 25%
Shenzhen • 25%
Guangzhou • 25%